Evidence map›Paper›PMID 40436227›Full record

ArticleProtein expression and purification2025

Optimization of CYP27A1 recombinant protein expression.

Johanna E Papa, Lindsay R Vaughn, Jackson L Bartholomew-Schoch, Emma K Stone, Megen A Culpepper, Michael J Reddish

Abstract read
In one paragraph

Article in Protein expression and purification, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Johanna E PapaDepartment of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, USA.
Lindsay R VaughnDepartment of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, USA.
Jackson L Bartholomew-SchochDepartment of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, USA.
Emma K StoneDepartment of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, USA.
Megen A CulpepperDepartment of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, USA.
Michael J ReddishDepartment of Chemistry and Fermentation Sciences, Appalachian State University, Boone, NC, USA. Electronic address: reddishmj@appstate.edu.

Funding

Structure-Function Studies of the Human Cytochrome P450 27 FamilyR35GM147276 · NIGMS · APPALACHIAN STATE UNIVERSITY · PI Michael Jerrell Reddish · 2022 to 2026
$1.8M
NIGMS NIH HHS R35 GM147276
6 · The paper itself

Abstract

Human mitochondrial cytochrome P450 27A1 is a monooxygenase enzyme that oxidizes bile acids and other sterol derivatives. The enzyme plays an important role in sterol metabolism and is a potential target for clinical therapies related to metabolic conditions and certain cancers. To support the development of such therapies, detailed structural and functional studies of the enzyme should be pursued. Producing large quantities of purified, recombinant enzyme would enable these studies. Recombinant production of human cytochrome P450 27A1 in E. coli is challenging due to the enzyme being membrane associated. This work explores the optimization of human cytochrome P450 27A1 expression in E. coli by systematically testing the effects of cell strain, expression temperature, concentrations of induction reagents, and expression times. Western blot analysis is used to investigate the effects of variable changes prior to purification. E. coli cell strain (switching to C41(DE3)) appears to have the largest positive effect on overall yield. Increasing δ-aminolevulinic acid concentration (induces heme synthesis) also leads to significantly increased yields. Decreasing expression time decreases the amount of higher order cytochrome P450 aggregates that are formed. The combination of these changes is a more robust expression protocol with three major advantages: decreased expression time, lower aggregate to monomer ratios, and increased overall yield.

Indexed as

Cholestanetriol 26-MonooxygenaseRecombinant ProteinsAminolevulinic AcidEscherichia coliGene ExpressionHumansAminolevulinic AcidCholestanetriol 26-MonooxygenaseCYP27A1 protein, humanRecombinant Proteins

Identifiers

PMID40436227
PMCPMC12188933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.